STF Management LP Lowers Stock Position in Amgen Inc. $AMGN

STF Management LP lowered its position in Amgen Inc. (NASDAQ:AMGN) by 64.7% in the 4th quarter, HoldingsChannel.com reports. The firm owned 2,831 shares of the medical research company’s stock after selling 5,198 shares during the period. Amgen comprises about 0.9% of STF Management LP’s portfolio, making the stock its 26th largest holding. STF Management LP’s holdings in Amgen were worth $927,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in AMGN. Capital World Investors raised its holdings in shares of Amgen by 11.5% in the third quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock valued at $5,303,578,000 after purchasing an additional 1,935,876 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Amgen by 1.8% in the fourth quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock valued at $17,949,296,000 after purchasing an additional 961,975 shares during the last quarter. National Bank of Canada FI raised its holdings in shares of Amgen by 237.7% in the third quarter. National Bank of Canada FI now owns 1,226,372 shares of the medical research company’s stock valued at $346,076,000 after purchasing an additional 863,216 shares during the last quarter. Van ECK Associates Corp grew its holdings in shares of Amgen by 71.8% in the third quarter. Van ECK Associates Corp now owns 1,358,092 shares of the medical research company’s stock valued at $383,254,000 after acquiring an additional 567,400 shares in the last quarter. Finally, Fisher Asset Management LLC grew its holdings in shares of Amgen by 91.6% in the third quarter. Fisher Asset Management LLC now owns 785,284 shares of the medical research company’s stock valued at $221,607,000 after acquiring an additional 375,463 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $326.31 on Friday. The stock has a fifty day simple moving average of $349.17 and a two-hundred day simple moving average of $342.99. Amgen Inc. has a 1-year low of $267.73 and a 1-year high of $391.29. The firm has a market cap of $176.10 billion, a price-to-earnings ratio of 22.71, a price-to-earnings-growth ratio of 3.28 and a beta of 0.44. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The business had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. During the same period in the prior year, the company earned $4.90 earnings per share. Amgen’s revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Analysts anticipate that Amgen Inc. will post 22.37 earnings per share for the current year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 3.1%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s dividend payout ratio is 70.15%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on AMGN shares. Wells Fargo & Company upped their target price on Amgen from $375.00 to $390.00 and gave the company an “equal weight” rating in a report on Thursday, March 19th. Daiwa Securities Group reduced their target price on Amgen from $410.00 to $390.00 and set an “outperform” rating for the company in a report on Wednesday. Canaccord Genuity Group started coverage on Amgen in a report on Monday, April 20th. They issued a “hold” rating and a $366.00 target price for the company. Piper Sandler reduced their target price on Amgen from $432.00 to $427.00 and set an “overweight” rating for the company in a report on Thursday. Finally, Jefferies Financial Group assumed coverage on shares of Amgen in a research report on Tuesday, March 10th. They set a “hold” rating and a $350.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $356.15.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the transaction, the senior vice president owned 7,009 shares in the company, valued at $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.85% of the company’s stock.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.